These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 9558126

  • 1. A model for the prediction of digoxin-drug interactions at the renal tubular cell level.
    Woodland C, Ito S, Koren G.
    Ther Drug Monit; 1998 Apr; 20(2):134-8. PubMed ID: 9558126
    [Abstract] [Full Text] [Related]

  • 2. The digoxin-propafenone interaction: characterization of a mechanism using renal tubular cell monolayers.
    Woodland C, Verjee Z, Giesbrecht E, Koren G, Ito S.
    J Pharmacol Exp Ther; 1997 Oct; 283(1):39-45. PubMed ID: 9336306
    [Abstract] [Full Text] [Related]

  • 3. Toxic digoxin-drug interactions: the major role of renal P-glycoprotein.
    Koren G, Woodland C, Ito S.
    Vet Hum Toxicol; 1998 Feb; 40(1):45-6. PubMed ID: 9467211
    [Abstract] [Full Text] [Related]

  • 4. P-glycoprotein as the mediator of itraconazole-digoxin interaction.
    Angirasa AK, Koch AZ.
    J Am Podiatr Med Assoc; 2002 Sep; 92(8):471-2. PubMed ID: 12237270
    [No Abstract] [Full Text] [Related]

  • 5. The mechanism of the verapamil-digoxin interaction in renal tubular cells (LLC-PK1).
    Ito S, Woodland C, Harper PA, Koren G.
    Life Sci; 1993 Sep; 53(24):PL399-403. PubMed ID: 8246676
    [Abstract] [Full Text] [Related]

  • 6. P-glycoprotein-mediated renal tubular secretion of digoxin: the toxicological significance of the urine-blood barrier model.
    Ito S, Woodland C, Harper PA, Koren G.
    Life Sci; 1993 Sep; 53(2):PL25-31. PubMed ID: 8100040
    [Abstract] [Full Text] [Related]

  • 7. From bench to bedside: utilization of an in vitro model to predict potential drug-drug interactions in the kidney: the digoxin-mifepristone example.
    Woodland C, Koren G, Ito S.
    J Clin Pharmacol; 2003 Jul; 43(7):743-50. PubMed ID: 12856388
    [Abstract] [Full Text] [Related]

  • 8. Energy-dependent transport of digoxin across renal tubular cell monolayers (LLC-PK1).
    Ito S, Koren G, Harper PA, Silverman M.
    Can J Physiol Pharmacol; 1993 Jan; 71(1):40-7. PubMed ID: 8099844
    [Abstract] [Full Text] [Related]

  • 9. Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein.
    Ushigome F, Takanaga H, Matsuo H, Yanai S, Tsukimori K, Nakano H, Uchiumi T, Nakamura T, Kuwano M, Ohtani H, Sawada Y.
    Eur J Pharmacol; 2000 Nov 10; 408(1):1-10. PubMed ID: 11070177
    [Abstract] [Full Text] [Related]

  • 10. Characterisation of (R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein.
    Bachmakov I, Rekersbrink S, Hofmann U, Eichelbaum M, Fromm MF.
    Naunyn Schmiedebergs Arch Pharmacol; 2005 Mar 10; 371(3):195-201. PubMed ID: 15900513
    [Abstract] [Full Text] [Related]

  • 11. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin.
    de Lannoy IA, Silverman M.
    Biochem Biophys Res Commun; 1992 Nov 30; 189(1):551-7. PubMed ID: 1360207
    [Abstract] [Full Text] [Related]

  • 12. Current status of cardiac glycoside drug interactions.
    Hooymans PM, Merkus FW.
    Clin Pharm; 1985 Nov 30; 4(4):404-13. PubMed ID: 2412751
    [Abstract] [Full Text] [Related]

  • 13. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein.
    Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, Fromm MF.
    J Pharmacol Exp Ther; 2000 May 30; 293(2):376-82. PubMed ID: 10773005
    [Abstract] [Full Text] [Related]

  • 14. Physiologically-based pharmacokinetic modeling to evaluate in vitro-to-in vivo extrapolation for intestinal P-glycoprotein inhibition.
    Yamazaki S, Evers R, De Zwart L.
    CPT Pharmacometrics Syst Pharmacol; 2022 Jan 30; 11(1):55-67. PubMed ID: 34668334
    [Abstract] [Full Text] [Related]

  • 15. Estradiol regulation of P-glycoprotein expression in mouse kidney and human tubular epithelial cells, implication for renal clearance of drugs.
    Kanado Y, Tsurudome Y, Omata Y, Yasukochi S, Kusunose N, Akamine T, Matsunaga N, Koyanagi S, Ohdo S.
    Biochem Biophys Res Commun; 2019 Nov 12; 519(3):613-619. PubMed ID: 31540689
    [Abstract] [Full Text] [Related]

  • 16. Clinical pharmacokinetic significance of the renal tubular secretion of digoxin.
    Koren G.
    Clin Pharmacokinet; 1987 Nov 12; 13(5):334-43. PubMed ID: 3319348
    [Abstract] [Full Text] [Related]

  • 17. Interactions of 1-methyl-4-phenylpyridinium and other compounds with P-glycoprotein: relevance to toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Staal RG, Yang JM, Hait WN, Sonsalla PK.
    Brain Res; 2001 Aug 10; 910(1-2):116-25. PubMed ID: 11489261
    [Abstract] [Full Text] [Related]

  • 18. Mixed-effect modeling for detection and evaluation of drug interactions: digoxin-quinidine and digoxin-verapamil combinations.
    Bauer LA, Horn JR, Pettit H.
    Ther Drug Monit; 1996 Feb 10; 18(1):46-52. PubMed ID: 8848820
    [Abstract] [Full Text] [Related]

  • 19. Lack of interaction of digoxin and P-glycoprotein inhibitors, quinidine and verapamil in human placenta in vitro.
    Holcberg G, Sapir O, Tsadkin M, Huleihel M, Lazer S, Katz M, Mazor M, Ben-Zvi Z.
    Eur J Obstet Gynecol Reprod Biol; 2003 Aug 15; 109(2):133-7. PubMed ID: 12860328
    [Abstract] [Full Text] [Related]

  • 20. Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression.
    Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K.
    Eur J Pharm Sci; 2002 Aug 15; 16(3):159-65. PubMed ID: 12128170
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.